Longboard Pharmaceuticals, Inc. Net Income
| Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|
| Net Income | ($14.4M) | ($27.7M) | ($43.1M) | ($54.4M) |
Longboard Pharmaceuticals, Inc. (LBPH) Net Income comparison analysis
General
LTM Net Income
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
LBPH key stats
| Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.0 | 0.0 |
% margin | 0.0 0.0% | (0.0) 0.0% | (0.0) 0.0% | (0.0) 0.0% |
| Operating Expenses | 14.4 | 27.8 | 44.8 | 56.8 |
| Research & Development Expenses (R&D) | 4.6 | 19.8 | 34.6 | 43.8 |
| Selling, General & Administrative Expenses (SG&A) | 9.8 | 8.1 | 10.2 | 13.0 |
% margin | (14.4) 0.0% | (27.8) 0.0% | (44.8) 0.0% | (56.8) 0.0% |
| Interest Income | 0.0 | 0.1 | 0.8 | 2.4 |
| Interest Expense | 0.0 | 0.0 | 0.8 | 0.0 |
| Pre-tax Income | (14.4) | (27.8) | (43.9) | (54.4) |
% effective tax rate | (0.0) 0.1% | (0.1) 0.2% | (0.9) 1.9% | 0.0 0.0% |
% margin | (14.4) 0.0% | (27.7) 0.0% | (43.1) 0.0% | (54.4) 0.0% |
| EPS | (0.82) | (1.62) | (2.51) | (2.39) |
| Diluted EPS | (0.82) | (1.62) | (2.51) | (2.39) |
% margin | (14.4) 0.0% | (27.8) 0.0% | (44.8) 0.0% | (56.8) 0.0% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
FAQ
1) What is Longboard Pharmaceuticals, Inc.'s Net Income?
As of today, Longboard Pharmaceuticals, Inc.'s last 12-month Net Income is ($76.3M), based on the financial report for Sep 30, 2024 (Q3’2024).
2) What is Longboard Pharmaceuticals, Inc.'s Net Income growth rate?
Over the last year, Longboard Pharmaceuticals, Inc.'s Net Income growth was 53.2%. The average annual Net Income growth rates for Longboard Pharmaceuticals, Inc. have been 56.5% over the past three years, 237.6% over the past five years.
3) Is Longboard Pharmaceuticals, Inc.'s Net Income growth rate Good?
Over the last year, Longboard Pharmaceuticals, Inc.'s Net Income growth was 53.2%, which is higher than industry growth of (0.1%). It indicates that Longboard Pharmaceuticals, Inc.'s Net Income growth is Good.